Search
forResearch 10 of 1000+
- Controversy: Synthetic hairs and their role in hair restoration?
- View Point- Synthetic hairs: Should they be used?
- Synthetic Hairs: Their Role in Hair Restoration
- Arterielles popliteales Entrapment Syndrom (PAES) — ein Fallbericht zur Differentialdiagnose der Claudicatio intermittens
- Artificial Hair: By the Dawn to Automatic Biofibre® Hair Implant
- Artificial hair implantation for hair restoration
- Drugs that affect autonomic functions or the extrapyramidal system
- Current Status of Hair Restoration Surgery
- Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
- The Efficacy of Baricitinib as a Treatment Option for Alopecia, In Terms of Promoting Hair Regrowth and Improving Patient Reported Outcomes
Learn 1 of 21
All learn results →Community 10 of 75
- Just FYI, Here are pictures of 6 months results on Clascoterone 5%. Is it remarkable? No. But it seems likely to be FDA approved considering 1% is already available. This is a win, especially if you pair it with other treatments like Finasteride.
- New warning by FDA on topical finasteride
- Dutasteride would have been approved for AGA by the US FDA.
- Finasteride alternative close to fda approval in the US
- Peeps who arent able to get gains even after using fda approved meds
- Following the recent IPO and the positive Phase 3 clinical data for VDPHL01 (extended-release oral minoxidil), what is the projected timeline for the FDA submission and the subsequent commercial availability on the market?
- FDA Policy Shift Explained: What It Actually Means for PP405, VDPHL-01, Breezula and Hair Loss Drug Timelines
- There’s actually a quite good chance that next year, we might see a new treatment get FDA approval for the first time in nearly three decades.
- Good news for stem cells hair therapies - US federal judge: using patients' stem cells does NOT fall under FDA jurisdiction
- US FDA will now default to only one clinical trial for drug applications, will this accelerate the release of PP405 and other drugs in clinical trials?